Novel bromomelatonin derivatives suppress osteoclastic activity and increase osteoblastic activity: implications for the treatment of bone diseases

Receptor activator of nuclear factor-κB

Receptor activator of nuclear factor-κB ligand and osteoprotegerin : Potential implications for the pathogenesis and treatment of malignant bone diseases

✍ Lorenz C. Hofbauer; Andreas Neubauer; Armin E. Heufelder 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 1 views

## Background: The current review summarizes the roles of the ligand, receptor activator of nuclear factor-kappab ligand (rankl), its receptor, receptor activator of nuclear factor-kappab (rank), and its decoy receptor, osteoprotegerin (opg), on osteoclast biology and bone resorption. furthermore,